Last reviewed · How we verify

Relapsing remitting multiple sclerosis — Treatment Landscape & Competitive Intelligence

Relapsing remitting multiple sclerosis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Relapsing remitting multiple sclerosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Zeposia OZANIMOD Bristol-Myers Squibb Sphingosine 1-phosphate Receptor Modulator Sphingosine 1-phosphate receptor 1 2020-01-01
Mayzent SIPONIMOD Novartis Sphingosine 1-phosphate Receptor Modulator [EPC] Sphingosine 1-phosphate receptor 1 2019-01-01
Plegridy PEGINTERFERON BETA-1A Biogen Idec Inc Interferon beta [EPC] Interferon alpha/beta receptor 2014-01-01
Tecfidera DIMETHYL FUMARATE Biogen dimethyl fumarate Hydroxycarboxylic acid receptor 2 2013-01-01
Aubagio TERIFLUNOMIDE Sanofi Pyrimidine Synthesis Inhibitor [EPC] dihydroorotate dehydrogenase 2012-01-01
Gilenya FINGOLIMOD Novartis Sphingosine 1-phosphate Receptor Modulator Sphingosine 1-phosphate receptor 1 2010-01-01
Campath ALEMTUZUMAB Sanofi CD52-directed Cytolytic Antibody [EPC] CAMPATH-1 antigen 2001-01-01
Zenapax DACLIZUMAB Hoffman-La Roche Interleukin-2 Receptor Blocking Antibody Interleukin-2 receptor 1997-01-01
Avonex INTERFERON BETA-1A Biogen Interferon beta [EPC] Interferon alpha/beta receptor 1996-01-01
Betaseron INTERFERON BETA-1B Bayer Healthcare Pharms Interferon beta Interferon alpha/beta receptor 1993-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Biogen · 3 drugs in Relapsing remitting multiple sclerosis
  2. Novartis · 2 drugs in Relapsing remitting multiple sclerosis
  3. Sanofi · 2 drugs in Relapsing remitting multiple sclerosis
  4. · 2 drugs in Relapsing remitting multiple sclerosis
  5. EMD Serono Research & Development Institute, Inc. · 1 drug in Relapsing remitting multiple sclerosis
  6. Hoffman-La Roche · 1 drug in Relapsing remitting multiple sclerosis
  7. Holy Name Medical Center, Inc. · 1 drug in Relapsing remitting multiple sclerosis
  8. National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in Relapsing remitting multiple sclerosis
  9. National Institute of Neurological Disorders and Stroke (NINDS) · 1 drug in Relapsing remitting multiple sclerosis
  10. Novartis Pharmaceuticals · 1 drug in Relapsing remitting multiple sclerosis
  11. Teva · 1 drug in Relapsing remitting multiple sclerosis
  12. US Department of Veterans Affairs · 1 drug in Relapsing remitting multiple sclerosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Relapsing remitting multiple sclerosis:

Cite this brief

Drug Landscape (2026). Relapsing remitting multiple sclerosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/relapsing-remitting-multiple-sclerosis. Accessed 2026-06-09.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing